Zmapp

ZMapp is an experimental serum mixture of three humanized monoclonal antibodies for immunological protection against the Ebola virus.[1][2][3] On 31 July 2014 the drug was first tested on humans. It was administered to two Americans who had been infected with Ebola. Both patients appeared to have had positive results.[4][5]

The ZMapp drug is being developed by Mapp Biopharmaceutical Inc., a result of the collaboration between Mapp Biopharmaceutical (San Diego), LeafBio (the commercial arm of Mapp Biopharmaceutical), Defyrus Inc. (Toronto), the U.S. government and the Public Health Agency of Canada.[1] The antibody work came out of research projects funded by the U.S. Army more than a decade ago.[6] The Defense Threat Reduction Agency (DTRA) announced additional funds to Mapp Biopharmaceutical based on the "promising results".[7]

Print this Page

All Treatments

Average Effectiveness

This is the Average effectiveness per ailment as reported by our participants (you).

Effectiveness:
  • 0 = No improvement or Worse
  • 1 = Slight improvement
  • 2 = Moderate Improvement
  • 3 = Significant Improvement
  • 4 = Cured

Order By

Type of Treatment

Date Range

Minimum Number of Users

Embed

Complete a survey on Zmapp to help the CureCrowd community

If you have tried to treat this ailment, please complete the following form to help us better our data, and help guide people to the best possible treatments. CureCrowd is a public resource with absolutely no vested interest in the outcomes of our studies.